These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8038709)

  • 1. The interleukin-1 receptor antagonist and its delivery by gene transfer.
    Evans CH; Robbins PD
    Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
    Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
    Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.
    Burger D; Chicheportiche R; Giri JG; Dayer JM
    J Clin Invest; 1995 Jul; 96(1):38-41. PubMed ID: 7615809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1 receptor antagonism.
    Nikolic-Paterson DJ; Lan HY; Atkins RC
    Semin Nephrol; 1996 Nov; 16(6):583-90. PubMed ID: 9125803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist.
    Chole RA; Faddis BT; Tinling SP
    J Bone Miner Res; 1995 Feb; 10(2):281-4. PubMed ID: 7754808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.
    Ricci S; Macchia G; Ruggiero P; Maggi T; Bossù P; Xu L; Medaglini D; Tagliabue A; Hammarström L; Pozzi G; Boraschi D
    BMC Biotechnol; 2003 Sep; 3():15. PubMed ID: 13129437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
    Svenson M; Nedergaard S; Heegaard PM; Whisenand TD; Arend WP; Bendtzen K
    Eur J Immunol; 1995 Oct; 25(10):2842-50. PubMed ID: 7589081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer.
    Gouze JN; Gouze E; Palmer GD; Liew VS; Pascher A; Betz OB; Thornhill TS; Evans CH; Grodzinsky AJ; Ghivizzani SC
    Arthritis Res Ther; 2003; 5(5):R301-9. PubMed ID: 12932294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist.
    Kim JM; Jeong JG; Ho SH; Hahn W; Park EJ; Kim S; Yu SS; Lee YW; Kim S
    Gene Ther; 2003 Sep; 10(18):1543-50. PubMed ID: 12907945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
    Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
    Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo.
    Gabay C; Porter B; Fantuzzi G; Arend WP
    J Immunol; 1997 Dec; 159(12):5905-13. PubMed ID: 9550387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
    Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP
    Arthritis Rheum; 2001 Feb; 44(2):451-62. PubMed ID: 11229477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
    Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
    Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
    Yamada J; Zhu SN; Streilein JW; Dana MR
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II.
    Ruggiero P; Bossù P; Macchia G; Del Grosso E; Sabbatini V; Bertini R; Colagrande A; Bizzarri C; Maurizi G; Di Cioccio V; D'Andrea G; Di Giulio A; Frigerio F; Grifantini R; Grandi G; Tagliabue A; Boraschi D
    J Immunol; 1997 Apr; 158(8):3881-7. PubMed ID: 9103457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist protein.
    Shuck ME; Eessalu TE; Tracey DE; Bienkowski MJ
    Eur J Immunol; 1991 Nov; 21(11):2775-80. PubMed ID: 1834470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist.
    Raibekas AA; Bures EJ; Siska CC; Kohno T; Latypov RF; Kerwin BA
    Biochemistry; 2005 Jul; 44(29):9871-9. PubMed ID: 16026159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 and interleukin-1 receptor antagonist.
    Dinarello CA
    Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: MFG-IRAP, University of Pittsburgh.
    Baragi VM
    Curr Opin Mol Ther; 2000 Apr; 2(2):216-20. PubMed ID: 11249645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism.
    Dinarello CA
    Int J Tissue React; 1992; 14(2):65-75. PubMed ID: 1399323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.